Celltrion seeks bigger footing in South Africa
Celltrion announced Thursday that the company has won public tenders in Peru to provide its autoimmune disease treatment Remsima (infliximab) and anticancer product Herzuma (trastuzumab) to the South American country. According to Celltrion, Remsima has won a tender held by the Peruvian Workers' Insurance System (EsSalud), which is the largest of its kind, accounting for 81 percent of the total infliximab volume in Peru. The company will supply Remsima for a year starting this month. Celltr
May 2, 2024